Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for CRHBP Antibody [Unconjugated]
corticotropin releasing hormone binding protein
corticotropin-releasing factor-binding protein
Corticotropin-releasing hormone-binding protein
CRFBPcorticotropin releasing hormone-binding protein
Human CRHBP is a 37 kDa secreted glycoprotein that likely serves to regulate CRH availability to the adrenal. In human, CRHBP complexes with CRH to form a circulating 41 kDa complex. In rodent and horse, this complex is restricted to the CNS. Human CRHBP is synthesized as a 322 amino acid (aa) precursor that contains a 24 aa signal sequence and a 298 aa mature region. The mature region contains one potential CUB domain and five intrachain disulfide bonds. Human mature CRHBP shares 87% and 84% sequence identity with mouse and equine CRHBP, respectively.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our CRHBP Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.